Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Significant Increase in Short Interest

Indaptus Therapeutics, Inc. (NASDAQ:INDP) saw a large increase in short interest in the month of March. As of March 31st, there was short interest totaling 13,325 shares, an increase of 54.2% from the March 15th total of 8,642 shares. Approximately 0.8% of the shares of the company are short sold. Based on an average daily trading volume, of 18,013 shares, the short-interest ratio is currently 0.7 days.

Institutional Trading of Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics at the end of the most recent quarter. 7.06% of the stock is currently owned by hedge funds and other institutional investors.

Indaptus Therapeutics Trading Up 16.3%

INDP opened at $2.71 on Thursday. The stock has a market cap of $6.08 million, a PE ratio of -0.11 and a beta of 0.97. Indaptus Therapeutics has a 1 year low of $1.51 and a 1 year high of $19.91. The stock’s 50 day simple moving average is $1.85 and its 200-day simple moving average is $2.47.

Indaptus Therapeutics (NASDAQ:INDP) last released its quarterly earnings data on Tuesday, March 17th. The company reported ($3.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.36) by $1.26. Equities analysts forecast that Indaptus Therapeutics will post -1.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.